Skip to main content

Anti-Rheumatic Rx

Night Splinting for Carpal Tunnel (3.24.2023)

Mar 24, 2023

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com.  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.




  1. 29 pts w/ PsA Sine Psoriasis: 16F/13M, mean age 45 yrs w/

Read Article

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA

MedPage Today
Mar 23, 2023

Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.

Read Article

Updated AAV Treatment Recommendations

EurekAlert!
Mar 22, 2023

AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). This variety can make management challenging.

Read Article

Metformin Reduces Osteoarthritis Risk

MedPage Today
Mar 21, 2023

Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported.



In a retrospective cohort study of nearly 21,000 adults with diabetes, those who were taking metformin saw a 24% lower risk for developing OA compared with those taking a

Read Article
#RNL2023 Year in Review COMPLETE-PsA: DMARDs for PsA! LEF+MTX better than MTX alone, 78 total patients PASDAS at week 16: 59% for MTX+LEF vs 34% MTX+PBO More treatment discontinuations (10 vs 3) in combo group due to GI intolerance @RheumNow https://t.co/3Al8PQmNli
#ClinicalPearl #Methotrexate weekly May reduce side effects in rapidly dividing cells vs using it daily or every few days. GI, oral, bone marrow side effects should be less if once a week. Joel Kremer ⁦@RheumNow⁩ #RNL2023 https://t.co/i0LZoQuK0w
Tremendously emotional (and unfiltered) first person account of his fight with COVID-19 by Miracle Larry who thanked our Dr. Cush @RheumNow for his ingenuity in fighting COVID-19, thanking healthcare workers for all they do, and reminding us to be empathic. #RNL2023 https://t.co/i0D7r8dR8n
RBC MTX polyglutamate levels may be the “truth serum” for those pts stating they are taking their MTX but you question it. Dr. Kremer @RheumNow #RNL2023
Dr. Carol Langford on GPA treatment Duration of remission maintenance therapy? - at least 2 years, after 2 years, maintenance appropriate in many cases - consider RTX, and other cDMARDs (MTX, MMF, AZA) @RheumNow #RNL2023 https://t.co/VmswcnzN5v
Is there role for MTX in GCA Favorable results in a meta-analysis with NNT 11 to prevent 1 cranial relapse BUT: limitations of meta-analysis, short follow-up, dose response not evaluated Robert Spiera at #RNL2023 @RheumNow https://t.co/sHx2ceVmAi
DMARDs/TNF for PMR: MTX- initial benefit, but no 5 year steroid sparing effect Infliximab - no benefit Lef - some benefit in case series Robert Spiera #RNL2023 @RheumNow https://t.co/cmwGEWHQEO
MTX as a treatment of OA, by Dr.Conaghan #RNL2023 ⁦@RheumNow⁩ Systemic inflammation might also be a part of OA?! https://t.co/grxMKtRLhj
Conaghan shares unpublished data from PROMOTE study at #RNL2023 Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active. Looking forward to more data on this - though many many many DMARD trials thus far have been disappointing in OA @RheumNow https://t.co/Ieagp8mq31

2022 EULAR Recommendations for ANCA-associated Vasculitis

Mar 16, 2023

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).



AAV recommendations were last published in 2016, and since, research and clinical trials have advanced our understanding of AAV.  A

Read Article

Polypharmacy Increased in Psoriatic Arthritis

Mar 16, 2023

Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.



A study of 11,984 PsA patients in the German BARMER health insurance database from 2021 compared medicines and comorbidities

Read Article
Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases. https://t.co/jpxQggd89T https://t.co/zjer5QTN3C

A Pilot Trial of Anifrolumab in Discoid Lupus

Mar 15, 2023

A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). 

Read Article

Itaconate - A Potential New Immunosuppressive

EurekAlert!
Mar 15, 2023

Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate (ITA) on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.

Read Article

Cost-Effective Use of Biological and Targeted Synthetic DMARDs

Mar 14, 2023

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid

Read Article

Carpal Tunnel - Steroid injection vs. Night Splinting

Mar 13, 2023

A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS

Read Article
Does Methotrexate Work in Alopecia Universalis? Alopecia areata totalis (AT) and universalis (AU) are the most severe and difficult to treat forms of alopecia areata (AA). https://t.co/Lvd7P6r85w https://t.co/hX3rz5fBKT
Does Methotrexate Work in Alopecia Universalis? Alopecia areata totalis (AT) and universalis (AU) are the most severe and difficult to treat forms of alopecia areata (AA). https://t.co/x8EjMekMBJ https://t.co/ntejSJcG5M

Big Time Vasculitis (3.10.2023)

Mar 10, 2023

Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?




Read Article

Long-Term Survival of Idiopathic Inflammatory Myopathies

Mar 09, 2023

A single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.



This was a retrospective single-centre analysis of IIM patients

Read Article

Glucocorticoid (GC)-free resolution of polymyalgia rheumatica (PMR) signs and symptoms in patients treated with sarilumab with history of flare: analysis from SAPHYR

Sponsored by Sanofi
Mar 09, 2023

The poster reports post-hoc results from the SAPHYR study on the resolution of PMR signs and symptoms regardless of glucocorticoid (GC) use and GC-free resolution of PMR signs and symptoms over time. GC-free resolution of PMR signs and symptoms was maintained from week 16 to week 52 in majority

Read Article
×